Company Filing History:
Years Active: 2008
Title: Innovations of Sang Hsu in TNF Signaling Pathways
Introduction
Sang Hsu, an accomplished inventor based in Lexington, MA, has made significant contributions to the field of biochemistry through his innovative research. His work has led to the development of a patent that addresses critical pathways involved in cellular signaling, particularly concerning tumor necrosis factor (TNF).
Latest Patents
Hsu holds one patent titled "N-TRADD Active Site and Uses Thereof." This invention pertains to the three-dimensional solution structure of the N-terminal domain of the TNFR-1 associated death domain protein, known as N-TRADD. The patent details the identification and characterization of a C-TRAF2 binding active site of N-TRADD. Further, it provides methods for utilizing these three-dimensional structures to design and select potent and selective inhibitors of TNF signaling pathways. Hsu's work could have significant implications for therapeutic approaches in treating various diseases influenced by TNF signaling.
Career Highlights
Sang Hsu has worked at Genetics Institute, Inc., where he has been involved in groundbreaking research initiatives. His focus on the molecular mechanisms underlying TNF signaling showcases his expertise in biochemistry and innovative problem-solving in research environments. His patent reflects a deep understanding of the complexities of cellular signaling and the potential for targeted therapies.
Collaborations
Throughout his career, Hsu has collaborated with notable colleagues such as Desiree H. H. Tsao and Jean-Baptiste Telliez. These partnerships highlight the collaborative nature of research in the biochemistry field, allowing for the exchange of ideas and expertise that enhance the research outcomes.
Conclusion
Sang Hsu's contributions to the understanding of TNF signaling pathways through his patent exemplify the significant impact that innovative research can have on the field of biochemistry. As he continues to collaborate and contribute within the industry, his work remains a valuable asset to both the scientific community and the development of new therapeutic strategies.